First Tracks climbs on ‘impressive’ celiac study data

Initial study findings strengthened some analysts’ belief that First Tracks’ drug, one of a few in development aimed at the protein CD122, might have “pipeline-in-a-product” potential. 

By Delilah Alvarado • Oct. 12, 2026

Bristol Myers dips on ‘confounding’ lung drug results

Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, adding to analyst questions about the therapy’s prospects.

By Jonathan Gardner • Oct. 12, 2026

Explore the Trendline➔

Radiopharmaceuticals

A series of technological advances have led to an explosion of scientific progress — and dealmaking — involving medicines that can precisely deliver radioactive materials into tumors.   

By BioPharma Dive staff

Argenx falls as Sjögren’s setback offsets celiac drug progress

A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ‘blockbuster expansion opportunity’ for Vyvgart. 

By Kristin Jensen • Oct. 8, 2026

A Takeda spinout builds case for its Parkinson’s drug

Cerevance plans to meet with the FDA to determine next steps for a new kind of medicine known as solengepras, now that it has Phase 3 data in hand.

By Jacob Bell • Oct. 7, 2026

ArriVent collapses on disappointing lung cancer data

More than half of the company’s value was wiped out by findings that appear to erase a chance to battle Johnson & Johnson and others for market share. 

By Delilah Alvarado • Oct. 6, 2026

Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial

The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.

By Jonathan Gardner • Oct. 6, 2026

[Podcast] (Season 2) The Progress Profile: Alzheimer’s Research in Focus

This podcast explores how leading Alzheimer’s experts are working to bridge the gap between clinical trial design and frontline care.

By BioPharma Dive's studioID • Oct. 6, 2026

Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data

The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer and Merck on nearly all bacterial strains in the first of three Phase 3 trials.

By Ben Fidler • Oct. 5, 2026

3 takeaways from a European obesity scientific meeting

Eli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their contenders.

By Jonathan Gardner • Oct. 1, 2026

HHS kicks off new programs to speed clinical trials as Chinese competition looms

The department is offering funding to teams with innovative proposals as it considers ending the traditional phased clinical trial system.

By Kristin Jensen • Oct. 1, 2026

Pfizer’s eczema drug clears skin in mid-stage trial

Detailed results are competitive with Dupixent and Ebglyss, but the drug lacks differentiation amid an increasingly competitive landscape, one analyst argued.

By Delilah Alvarado • Oct. 1, 2026

Bristol Myers trial revisions shake confidence in new class of fibrosis drugs

A spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in testing of Bristol Myers’ admilparant — though it’s unclear whether the drug was to blame. 

By Jonathan Gardner • Sept. 30, 2026

Kodiak skyrockets on positive study data for 2 eye drugs

The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.

By Jonathan Gardner • Sept. 28, 2026

An ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus

Data from an early trial showed the company’s “gamma delta” cell therapy surpassed benchmarks set by personalized CAR-T treatments tested in lupus.

By Gwendolyn Wu • Sept. 28, 2026

Merck reveals study success, and possible safety worries, for eye drug hopeful

A medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies in diabetic macular edema, though language regarding the drug’s safety stirred debate among analysts.

By Kristin Jensen • Sept. 24, 2026

Roche, Ionis RNA drug scores in kidney disease study

The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers. 

By Jonathan Gardner • Sept. 23, 2026

Amgen reports a Phase 3 win with Sjögren’s drug candidate

Dazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against the tough-to-treat autoimmune disorder.

By Gwendolyn Wu • Sept. 22, 2026

Viking shares surge on updated obesity drug data

Trial participants mostly kept their weight down after switching from a weekly shot to less frequent dosing — findings that could strengthen Viking’s “competitive positioning,” one analyst wrote. 

By Jonathan Gardner • Sept. 22, 2026

Celldex sinks as safety concerns cloud immune drug results

Though barzolvolimab displayed what one analyst described as the best efficacy results to date against chronic skin hives, treatment was also associated with two life-threatening anaphylaxis cases.

By Kristin Jensen • Sept. 22, 2026

Beacon eye gene therapy hits mark in late-stage study

Beacon claimed the findings represent the first time a treatment for X-linked retinitis pigmentosa, a rare and potentially blinding condition, met its main goal in a pivotal trial.

By Gwendolyn Wu • Sept. 21, 2026

Xenon shares fall following depression trial pause

The occurrence of “neuropsychiatric” adverse events in testing fueled investor doubts about a drug the FDA is already reviewing for a form of epilepsy.

By Jonathan Gardner • Sept. 18, 2026

Skyhawk racks up more support for Huntington’s drug

The Fidelity-backed biotech now has 15-month data from a small study of its RNA-splicing therapy.

By Jacob Bell • Sept. 16, 2026

WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight

The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.

By Ben Fidler , Jonathan Gardner • Sept. 15, 2026

Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results

As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings that impressed Wall Street.

By Jonathan Gardner • Sept. 14, 2026

AstraZeneca’s newly approved pill fails frontline breast cancer study

Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year. 

By Delilah Alvarado • Sept. 14, 2026